No Data
Nanxin Pharmaceutical: 2024 Annual Results Forecast Announcement
2024 Annual Results Forecast Announcement
Hunan Nucien Pharmaceutical Gets China Marketing Nod for Anti-Allergy Drug
Hunan Nucien Pharmaceutical Co., Ltd. (688189.SH): Hydrochloride Fexofenadine oral suspension has obtained the Pharmaceutical registration certificate.
Gelonghui, on January 3rd, reported that Hunan Nucien Pharmaceutical Co., Ltd. (688189.SH) announced that its subsidiary, Guangzhou Nucien Pharmaceutical Co., Ltd., received the drug registration certificate for oral suspension of fexofenadine hydrochloride issued by the National Medical Products Administration. The indications for oral suspension of fexofenadine hydrochloride include: (1) relief of symptoms associated with seasonal allergic rhinitis in children aged 2 years and older and adults. (2) relief of skin symptoms of chronic idiopathic urticaria in children aged 6 months and older and adults, which can reduce itching and decrease the number of hives. Fexofenadine hydrochloride is a selective H1 receptor antagonist, which is the active form of terfenadine.
When will Hunan Nucien Pharmaceutical Co., Ltd. emerge from the shadow of losses after the termination and delay of core Innovative Drugs projects?
① Due to the high difficulty and slow progress of research and development, Hunan Nucien Pharmaceutical Co., Ltd. has terminated the development of the paramivir powder inhalation project. Additionally, due to stricter approval processes, the paramivir inhalation solution project will be postponed for two years. ② In the face of competition for paramivir injection, the adjustment of new drug projects will bring new uncertainties to the development of Hunan Nucien Pharmaceutical Co., Ltd.
Hunan Nucien Pharmaceutical Co., Ltd. (688189.SH): Plans to temporarily use up to 0.1 billion yuan of idle raised funds to supplement working capital.
Glory Financial reported on December 11 that Hunan Nucien Pharmaceutical Co., Ltd. (688189.SH) announced that the company intends to temporarily use no more than 100 million yuan (including the principal) of idle raised funds to supplement working capital, which is limited to the company's business expansion, daily operations, and other production activities related to the main business.
Hunan Nucien Pharmaceutical Co., Ltd. (SHSE:688189) May Have Run Too Fast Too Soon With Recent 29% Price Plummet